

00-00008

K974560

MAY 11 1998

Cordis
a Johnson-Johnson company

510(k) Summary of Safety and Effectiveness

General Information

Date: December 4, 1997

Manufacturers Address	Contact
Cordis Corporation 14201 NW 60th Avenue Miami Lakes, Florida 33014	Dennis Griffin

Proprietary Name	Common/Usual Name
Cordis Vanguard Steerable Guidewire	Catheter Guide Wire

Classification

Catheter Guide Wire
Class II, 21 CFR 870.1330, 74DQX

Predicate Devices

TAD II Guide Wire System 510K Number Unknown
Wholey Hi-Torque Guide Wire System K861765

Performance Standards

Performance standards have not been established by the FDA under section 514 of the Food and Drug Cosmetic Act.

Indications for Use

The Cordis Vanguard Guidewire is intended for use in angiographic procedures to introduce and position catheters and interventional devices within the peripheral vasculature.

Device Description

The Cordis Vanguard Steerable Guidewires have a multi-tapered stainless steel corewire with a soft, flexible, highly radiopaque platinum alloy coil over the tip. A steering / torquing device may be attached to aid in steering/torquing the guidewire.

Continued on next page



510(k) Summary of Safety and Effectiveness, Continued

Biocompatibility	All appropriate Biocompatibility tests were successfully performed on the materials used for the Cordis Vanguard Steerable Guidewires per ISO 10993-1.
-------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------

Summary of Substantial Equivalence	The Cordis Vanguard Steerable Guidewire is similar in design, construction, indication for use and performance characteristics to other commercially available <u>steerable</u> guidewires.
-------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

1

¹ Any statement of substantial equivalence to another product is required by 21 CFR 807.87, and relates only to whether the present product can be marketed without prior reclassification or clinical approval. The present submission is therefore not related to the coverage of any patent, and is not to be interpreted as an admission or used as evidence in a patent infringement lawsuit. As the Commissioner of the FDA has stated, "...a determination of substantial equivalence under the federal Food, Drug, and Cosmetic Act relates to the fact that the product can lawfully be marketed without pre-market approval or reclassification. This determination is not intended to have any bearing whatever on the resolution of patent infringement suits." 42 Fed. Reg. 42,520, et seq. (1977).



Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850

MAY 11 1998

Mr. Dennis S. Griffin
Manager, Regulatory and Clinical Affairs
Cordis Corporation
14201 N.W. 60th Avenue
Miami Lakes, FL 33014

Re: K974560
Trade Name: Cordis Vanguard Steerable Guidewires
Regulatory Class: II
Product Code: DQX
Dated: March 30, 1998
Received: March 31, 1998

Dear Mr. Griffin:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Pre-market Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act

for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4618. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,



Thomas J. Callahan, Ph.D.
Director
Division of Cardiovascular,
Respiratory and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATIONS FOR USE


510(K) Number (if known): [To be assigned by the FDA]

Device Name: Vanguard Steerable Guidewire

Indications for Use: The Cordis Vanguard Steerable Guidewires are designed for use in angiographic procedures to introduce and position catheters and interventional devices within the peripheral vasculature.

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation (ODE)



 (Division Sign-Off)
 Division of Cardiovascular, Respiratory,
 and Neurological Devices
 510(k) Number K974560

Prescription Use _____
(Per 21 CFR 801.109)

OR

Over-The Counter Use _____